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Objectives. This study was undertaken to determine whether the
presence of calcium in the mitral valve commissures, as demon-
strated echocardiographically, could predict outcome and to com-
pare this with an established echocardiographic scoring system.
Background. Percutaneous mitral balloon valvotomy is an
effective form of treatment for mitral valve stenosis. It is impor-
tant to identify patients who would benefit from this procedure.
Commissural splitting is the dominant mechanism by which
mitral valve stenosis is relieved by this technique, and thus
commissural morphology may predict outcome.
Methods. One hundred forty-nine consecutive patients who
underwent percutaneous mitral balloon valvotomy at the Mayo
Clinic were evaluated retrospectively. The morphology of the
mitral valve apparatus on the baseline echocardiograms was
scored in blinded manner using a semiquantitative grading sys-
tem of leaflet thickening, mobility, calcification and subvalvular
thickening (Abascal score). Additionally, each of the medial and
lateral commissures was graded for the presence or absence of
calcification. End points were death, New York Heart Association
functional class, repeat percutaneous mitral balloon valvotomy
and mitral valve replacement at follow-up.
Results. The mean follow-up period was 1.8 years (maximum
7.9 years). Univariate predictors of death and all events combined
included age, the use of a double-balloon technique, the presence
of calcium in a commissure and the Abascal score, as continuous
variables. Patients with an Abascal score <28 showed a trend
toward improved survival at 36 months free of death, repeat
percutaneous mitral balloon valvotomy or mitral valve replace-
ment (78 6 6% vs. 67 6 8%, p 5 0.07) and free of all events
combined (75 6 6% vs. 64 6 8%, p 5 0.07) versus those patients
with a score >8. However, survival at 36 months free of death,
repeat percutaneous mitral balloon valvotomy or mitral valve
replacement (86 6 4% vs. 40 6 4%) and free of all events
combined (82 6 5% vs. 38 6 10%) at follow-up was significantly
different between patients without commissural calcium and those
with commissural calcium (p < 0.001). In a Cox regression model
with Abascal score and commissural calcium and their interac-
tion, calcification emerged as the only significant variable (p <
0.01).
Conclusions. The presence of commissural calcium is a strong
predictor of outcome after percutaneous mitral balloon valvot-
omy. Patients with evidence of calcium in a commissure have a
lower survival rate and a higher incidence of mitral valve replace-
ment and all end points combined. Thus, the simple presence or
absence of commissural calcification assessed by two-dimensional
echocardiography can be used to predict outcome.
(J Am Coll Cardiol 1997;29:175–80)
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Percutaneous mitral balloon valvotomy has become an effec-
tive and established form of treatment for selected patients
with mitral valve stenosis (1–3). Randomized trials have shown
percutaneous mitral balloon valvotomy to be as effective as
closed or open commissurotomy in short-term follow-up for
patients with symptomatic mitral valve stenosis (4,5). The
beneficial differences in cost, length of hospital stay and return
to work from percutaneous mitral balloon valvotomy as com-
pared with surgical intervention make this catheter-based
therapy an attractive first-line procedure for patients with
severely symptomatic mitral stenosis. However, the immediate
success rate and long-term outcome of this procedure are
dependent on the underlying mitral valve morphology. Patients
with pliable, noncalcified mitral leaflets and no subvalvular
fusion will have a higher success rate and better long-term
results than those with thickened, immobile, calcified leaflets
with concomitant subvalvular fusion (1,3,6,7).
The mitral valve morphology in patients with mitral stenosis
is currently assessed in many institutions by the appearance of
the mitral valve apparatus on two-dimensional echocardiogra-
phy and is based on a mitral valve “score” in which leaflet
thickening, calcification and mobility as well as the degree of
subvalvular fusion are determined (1,3,6,7). A low score (#8)
is indicative of a pliable, noncalcified valve with little subval-
vular fusion and has been shown to be predictive of immediate
success as well as a low rate of restenosis. Higher scores, which
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are indicative of more calcified, immobile and thickened valve
leaflets with subvalvular fusion, have been shown to be asso-
ciated with a higher complication rate, a lower immediate
success rate and a higher rate of restenosis.
Despite the overall value of the mitral valve score, there
remain a number of patients with a relatively high mitral valve
score who will do well after mitral valvotomy (8). In addition,
there are patients with low mitral valve scores who may not do
well after mitral valvotomy. As commissural splitting is the
dominant mechanism by which mitral valve stenosis is relieved
by the balloon technique (9,10), assessment of the commissure
morphology should logically be an important part of the
evaluation of patients with mitral stenosis considered for
percutaneous mitral balloon valvotomy, and the commissural
appearance is a factor that is not directly assessed by the
Abascal score. Direct assessment of the mitral commissural
morphology by two-dimensional echocardiography was shown
in 30 patients to be a better predictor of immediate outcome
than the mitral echocardiographic score (11). However, there
have not been studies examining the effect of commissural
morphology on intermediate-term outcome in a larger group
of patients.
The purpose of this study was to determine the usefulness
of examining the morphology of the mitral valve commissures
for predicting outcome after percutaneous mitral balloon
valvotomy specifically assessing the presence or absence of
calcium in the commissures by two-dimensional echocardiog-
raphy. This new approach is compared to the currently estab-
lished echocardiographic scoring system (6,7).
Methods
Patient group. The study consisted of the first 149 consec-
utive patients who underwent percutaneous mitral balloon
valvotomy at the Mayo Clinic between September 1987 and
June 1995. All patients had symptomatic mitral stenosis and
underwent a comprehensive two-dimensional and Doppler
echocardiogram before the percutaneous mitral balloon valvo-
tomy. The decision to proceed with the valvotomy procedure
was made by one of three experienced operators based on the
clinical situation and the morphology of the mitral valve on
two-dimensional echocardiography. It has been previously
reported from our institution that all patients with severe
mitral stenosis were initially considered candidates for valvot-
omy irrespective of the mitral valve morphology (1,12). How-
ever, with experience, the procedure has been limited to
patients with pliable, minimally calcified valves or to those not
thought to be suitable candidates for mitral valve surgery. The
procedure of percutaneous mitral balloon valvotomy was ap-
proved by the Institutional Review Board of the Mayo Clinic.
Echocardiographic scoring. For this study, the morphology
of the mitral valve apparatus visualized on preprocedure
two-dimensional echocardiograms was retrospectively re-
viewed by two observers who had no knowledge of the
outcome of the procedure. A mitral valve score, as described
by Wilkins et al. (6) and Abascal et al. (7), was determined.
This score involves a semiquantitative grading of mitral valve
leaflet thickening, mobility, calcification and subvalvular thick-
ening, each on a scale of 1 to 4 with 1 being the least
involvement and 4 being the most severe involvement. The
total mitral valve score is the sum of these four individual
numbers. In addition, echocardiographic assessment of the
presence or absence of commissural calcification was per-
formed by directly examining the appearance of the medial and
lateral commissures on the two-dimensional echocardio-
graphic parasternal short-axis view, as has been previously
described (11). Echocardiographic calcium was defined as a
bright echocardiographic density (13) with acoustic shadowing.
The aortic root was used as a point of reference, and calcifi-
cation was said to be present if there was a brighter echocar-
diographic density in the commissures than was seen in the
adjacent aortic root. Specifically, the presence or absence of
calcification in each commissure was evaluated (Fig. 1).
Patients were classified into the following groups for the
purpose of outcome analysis: they were dichotomized into two
groups based on the Abascal score (score #8 vs. .8) and were
also dichotomized based on the presence or absence of com-
missural calcium.
Procedure. The double-balloon technique and the Inoue
single-balloon technique were both used as previously de-
scribed (1,14). The procedure was performed through an
anterograde approach across the mitral valve by performing a
transseptal puncture. For the double-balloon technique, the
balloon size was chosen using a nomogram, which incorpo-
rated the patient’s body surface area. The Inoue single-balloon
technique (14) included sequential increases in balloon size,
assessing the valve gradient and the degree of mitral regurgi-
Figure 1. A, Parasternal short-axis view of the mitral valve during
diastole (left) and systole (right) in a 32-year old woman with severe
mitral stenosis. Although thickening of the valve is present, there is no
calcification in either the lateral or medial commissures. B, Parasternal
short-axis view of the mitral valve during diastole (left) and systole
(right) in a 38-year old man with severe mitral stenosis. Calcification
and fusion are present in the lateral commissure, as marked by the
white arrows.
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tation after each inflation. Echocardiographic guidance was
employed in the majority of cases after December 1991 to
determine balloon position before and during inflation. Mitral
regurgitation was assessed by either a left ventriculogram or
color Doppler echocardiography after the procedure and
graded semiquantitatively on a scale from 1 to 4. Major
periprocedural complications were defined as in-hospital
death, cardiac tamponade, systemic embolism and an increase
in mitral regurgitation by two grades.
Follow-up analysis. Patients were contacted by telephone
every 6 months, and the majority were seen in clinical
follow-up at yearly intervals. End points at follow-up were
death, New York Heart Association functional class, repeat
percutaneous mitral balloon valvotomy and mitral valve re-
placement. Freedom from the combined end points of 1)
death, mitral valve replacement or repeat percutaneous mitral
balloon valvotomy, or 2) death, mitral valve replacement or
repeat percutaneous mitral balloon valvotomy and functional
class III or IV were also evaluated.
Statistics. Several preoperative variables were compared
with short-term results to assess the statistical significance of
differences and associations. For continuous variables, com-
parisons were made using two-tailed t tests if the data were
approximately gaussian. If the data were determined to be
non-gaussian, rank-sum tests were used. For categorical vari-
ables, tests for association were performed using the chi-square
test or the Fisher exact test, and the exact Wilcoxon rank-sum
test was used to analyze ordered categorical data. Kaplan-
Meier survival curves and Cox regression models were com-
puted for combined end points to identify predictors of
survival.
For the first analysis the end point was taken to be mitral
valve replacement, repeat percutaneous mitral balloon valvo-
tomy or death; otherwise the patients were censored at the
time of last known follow-up. For the second analysis the end
point was taken to be mitral valve replacement, repeat percu-
taneous mitral balloon valvotomy, death or functional class III
or IV; again, the patients not experiencing any of these end
points were censored at the time of last known follow-up.
Univariate analyses using the Cox model with Abascal score
(coded as 0 5 #8, and 1 5 .8) as the single covariate, and
another Cox model with calcification (coded as 05 no and 15
yes) as the single covariate, were performed initially.
Subsequently, two multivariate Cox models were evaluated
for each end point. First a main effects’ Cox model was run
with Abascal score and calcification as covariates. For both end
points, Abascal score was no longer significant and calcification
remained highly associated with the end point. In addition,
another Cox model was run for each end point with the two
main effect covariates and an interaction term. For both end
points there was no evidence of an interaction effect involving
Abascal score and calcification.
All Cox model analyses were performed using PROC
PHREG in SAS version 6.09.
Results
Study patients. One hundred and forty-nine patients un-
derwent percutaneous mitral balloon valvotomy. The average
patient age was 54.6 6 14 years (range 24 to 86). Before the
procedure, 5 patients (3%) were in functional class I, 48 (32%)
in class II, 87 (58%) in class III and 9 (6%) in class IV.
Eight-five patients were in normal sinus rhythm, 60 were in
atrial fibrillation and 4 had other rhythms (3 low atrial rhythms
and 1 paced rhythm). Twenty-three patients had undergone
prior mitral commissurotomy procedures, 16 of which had
been performed under open visualization.
Echocardiographic findings. Baseline echocardiograms
were available in 141 (95%) of the 149 patients. Ten studies for
commissural scoring and six studies for Abascal scoring were
assessed as having suboptimal image quality and were not
used. The average Abascal score was 8 6 2.1 (range 4 to 13).
Eighty-two patients (61%) had a score #8, whereas 32 (24%)
had an Abascal score $10. Twenty-nine patients (21%) had
calcification in either the medial or lateral mitral valve com-
missure (3 of these patients had bilateral commissural calcifi-
cation). Thirty-three patients (24%) had an Abascal grading
$3 for calcification, 16 of whom (48%) had the presence of
calcium in a commissure. Of the 32 patients with an Abascal
score $10, 14 (44%) had calcium present in a commissure.
Procedural results. Echocardiographic guidance was used
in 51 patients (34%). The mean mitral valve area of 1.1 6 0.36
cm2 before the procedure increased to 1.95 6 0.65 cm2 after
the procedure (p , 0.01). The mean mitral valve gradient of
13 6 5.8 mm Hg before the procedure was reduced to 6.1 6
3.5 mm Hg after the procedure (p , 0.1). In-hospital compli-
cations included death (2%), cardiac tamponade (3%) and
severe mitral regurgitation (6%). Four patients (3%) had a
technically unsuccessful procedure due to the inability to cross
the mitral valve with the balloon. Operative reports were
available in six patients who underwent mitral valve replace-
ment due to severe mitral regurgitation. The mechanism of
mitral regurgitation was identified to be secondary to torn
valve leaflets in four patients, a torn leaflet and chordae in one
patient and avulsion of the papillary muscle and left ventricular
rupture in one patient. All four patients with torn leaflets alone
had unilateral commissural calcification identified on echocar-
diography. Leaflet tears were related to the calcified commis-
sure if splitting occurred in that commissure (two patients) and
to the contralateral commissure if the calcified commissure did
not split (two patients). No echocardiographic commissural
calcification was seen in the patient with leaflet and chordal
tearing and dense calcification was noted in the lateral com-
missure of the last patient during the procedure.
The single-balloon technique (Inoue) was used in 99 pa-
tients (66%) and the double-balloon technique in 48 patients
(32%). A combination of both techniques was used in two
patients (1%). When comparing the type of balloon used
(single vs. double) there was no difference in final mitral valve
area (,1.5 vs. $1.5 cm2; p 5 0.8) or the combined end point
of mitral valve area, complications and procedural death (p 5
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0.6). However, there was a significant difference in freedom
from death, mitral valve replacement and percutaneous mitral
balloon valvotomy (p5 0.03) and all end points combined (p5
0.005) at last follow-up when comparing the single- versus the
double-balloon technique.
Follow-up. The mean follow-up period was 1.84 years
(range 30 days to 7.95 years). At last follow-up, 14 patients
(9%) were dead, 2 (1.5%) underwent a repeat percutaneous
mitral balloon valvotomy, 24 (16%) underwent mitral valve
replacement and 32 (21%) were functional class III or higher.
Echocardiographic predictors. Short-term results. When
Abascal score is taken as a discrete variable (#8, .8) and
compared with the final mitral valve area (,1.5, $1.5), low
values of Abascal score are significantly associated with high
values of the final mitral valve area (Fisher exact test, p 5
0.043). When Abascal score (#8, .8) is compared with the
multiple event end point of final mitral valve area (,1.5,$1.5),
complication (yes, no) or procedural death (yes, no), low
values of Abascal score are significantly associated with high
values of mitral valve area and no complications or deaths
(Fisher exact test, p , 0.01). The absence of commissural
calcification is also significantly associated with high values of
mitral valve area and no complications or deaths (Fisher exact
test, p , 0.01), but not with the final mitral valve area (,1.5,
$1.5) alone (p 5 NS). When the extent of commissural
calcification (unilateral vs. bilateral) is compared with the
multiple event end point just described, there is no significant
difference between the two subgroups (Fisher exact test, p 5
NS); however, patients with bilateral commissural calcification
were less likely to achieve a final mitral valve area $1.5 cm2
(Fisher exact test, p , 0.05).
Survival free of death, mitral valve replacement or repeat
percutaneous mitral balloon valvotomy. The 3-year Kaplan-
Meier estimate for overall survivorship free of death, mitral
valve replacement and repeat valvotomy is 69.9% (95% confi-
dence interval 60.4 to 80.2). The actuarial survival curves with
freedom from death, mitral valve replacement or repeat per-
cutaneous mitral balloon valvotomy for patients with Abascal
scores #8 and .8 are shown in Figure 2A. The 1-, 2- and
3-year Kaplan-Meier estimated actuarial event-free survival
rates were 93 6 3% versus 77 6 6%, 82 6 5% versus 71 6 7%
and 79 6 6% versus 67 6 8%, respectively (p 5 NS). In
contrast to these results, Figure 2B shows the estimated
actuarial event-free survival curves for those patients without
commissural calcium versus those patients with calcium in a
commissure. The 1-, 2- and 3-year Kaplan-Meier estimated
event-free actuarial survival rates were 93 6 3% versus 63 6
10%, 86 6 4% versus 53 6 10% and 86 6 4% versus 40 6
11%, respectively (p , 0.001). The results of the Cox regres-
sion support these Kaplan-Meier estimates. In a model with
Abascal score and commissural calcification and their interac-
tion, calcification is the only significant variable (p , 0.01).
Event-free survival. The 1-, 2- and 3-year Kaplan-Meier
estimated actuarial survival rates free of all events (death,
mitral valve replacement or repeat percutaneous mitral bal-
loon valvotomy and functional class III or IV) were 91 6 4%
versus 73 6 7%, 78 6 6% versus 67 6 7% and 75 6 6% versus
64 6 8%, respectively, for patients with Abascal scores #8 and
.8 (p 5 0.07). Similarly, these results are in sharp contrast
with the event-free survival rates of patients without calcium in
a commissure versus those with commissural calcium (906 3%
vs. 59 6 10%, 82 6 5% vs. 51 6 10% and 82 6 5% vs. 38 6
11%, respectively [p , 0.001]). Once again, in a model with
Abascal score and commissural calcification and their interac-
tion, calcification is the only significant variable (p , 0.01).
Discussion
Since the introduction of percutaneous mitral balloon val-
votomy by Inoue et al. (14) in 1984, the procedure has been
widely accepted as an effective therapy for mitral stenosis. In
two randomized studies percutaneous mitral balloon valvot-
omy has been shown to be as effective as open or closed mitral
commissurotomy (4,5). A number of previous studies have
shown that percutaneous mitral balloon valvotomy results in
satisfactory immediate- and long-term outcome (1–3,7,15,16)
with both the single- and double-balloon techniques. These
studies also highlighted subgroups of patients according to
clinical criteria that fared poorly with percutaneous mitral
balloon valvotomy, including the elderly, those with a history of
previous surgical commissurotomy and those in atrial fibrilla-
tion. Although these clinical variables are helpful, by far the
strongest independent predictor of outcome in these studies
has been the appearance of the mitral valve on two-
dimensional echocardiographic evaluation (1,3,6,7,16). Most
centers offering percutaneous mitral balloon valvotomy now
use the echocardiographic scoring system of Abascal et al. (7),
which involves a semiquantitative grading of mitral valve
leaflet thickening, mobility, calcification and subvalvular thick-
ening. Patients with a score#8 are considered good candidates
for the procedure and have been shown to have better
immediate- and long-term outcomes (3,6,7).
The dominant mechanism by which mitral valve stenosis is
relieved by the balloon technique is by splitting of the com-
missures (9,10). This study demonstrates the importance of the
assessment of mitral commissural morphology by two-
dimensional echocardiography before percutaneous mitral bal-
loon valvotomy, in addition to the more established methods of
mitral echocardiographic scoring. We specifically used the
presence or absence of commissural calcium as a simple
reproducible method for describing a valve with less likelihood
of responding to balloon valvotomy. Herein, there was a trend
but no significant difference in intermediate-term outcomes
between patients with a score #8 and those with a score .8.
This was in sharp contrast to a large difference in intermediate-
term outcomes between those patients with calcification in
commissures and those without calcification. These results
extend the observations of Fatkin et al. (11), who demon-
strated the influence of commissural calcification on the short-
term outcome in a series of 30 patients. Thus, a simple
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evaluation of the presence or absence of commissural calcium
on two-dimensional echocardiography is a better predictor of
intermediate-term outcome than the Abascal mitral echocar-
diographic score (7,8).
Previous studies on long-term outcome and mitral calcifi-
cation are limited. Tuzcu et al. (17) reviewed the association
between mitral valve calcification on fluoroscopy and long-
term outcome and found that survival rates became progres-
sively worse when severity of calcification increased. This series
did not take into account whether the calcification was in the
commissure, given the limitations of fluoroscopy. Post et al. (8)
reviewed the Inoue balloon registry and studied the outcome
of patients with Abascal scores $10, but also evaluated pa-
tients for the presence of commissural calcification as pro-
posed by the University of Southern California (USC) scoring
system (8). The immediate-term outcome success was inversely
proportional to the number of commissures with calcium;
however, the USC commissural score was not predictive of
long-term outcome. Finally, a study of patients developing
severe mitral regurgitation after percutaneous mitral balloon
valvotomy showed that of six patients requiring early mitral
valve replacement, five had evidence of commissural calcium
on pathologic examination (18).
Our study highlights the importance of examining the
presence or absence of calcification directly in the commissures
for selecting patients for percutaneous mitral balloon valvot-
omy. The present Abascal scoring system uses calcification as
one of four variables but does not differentiate between
calcium in the leaflets versus calcium directly in the commis-
sures. Of those patients in this study with significant calcifica-
tion recognized by the Abascal criteria (calcification subscore
$3), only 48% had calcium present in a commissure, placing
them in a more favorable risk group. Furthermore, of 32
patients with a high total Abascal score ($10), such as in the
group analyzed by Post et al. (8), only 14 (44%) had calcium
present in a commissure. Based on these observations it is our
recommendation to proceed with percutaneous mitral balloon
valvotomy if there is no commissural calcification, despite a
high Abascal score. In those patients with calcification in the
commissures, mitral valve replacement should be considered
Figure 2. A, Actuarial survival curves with freedom
from death, mitral valve replacement or repeat percu-
taneous mitral balloon valvuloplasty for patients with
Abascal scores #8 (solid line) or .8 (dashed line)
(p 5 NS). B, Actuarial survival curves with freedom
from death, mitral valve replacement or repeat valvu-
loplasty for patients without commissural calcium (sol-
id line) versus those patients with calcium in a com-
missure (dashed line) (p , 0.001).
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because the risk of complications in follow-up is increased.
However, if those patients with commissural calcification are at
high risk for open heart surgery, percutaneous mitral balloon
valvotomy could be considered if the physician and patient are
made aware of the higher risk and lower success rate. The
procedure should be performed beginning with smaller balloon
inflations and accepting final mitral valve areas than those seen
in patients without commissural calcification.
Study limitations. This was a retrospective study of a group
of referred patients and was subject to the drawbacks attrib-
uted to such a study. Sick, elderly and nonsurgical candidates
were prevalent among the earlier patients treated at our
institution before widespread acceptance of the procedure.
These patients who represent a higher risk group were also on
the steep portion of the learning curve that accompanies all
new procedures (12). Furthermore, the double-balloon tech-
nique was used in the majority of these earlier patients, and
although there was no difference in short-term outcome, the
significant difference in long-term outcome seen in these
patients compared with those in whom the single-balloon
technique was used should be interpreted with caution.
Routine follow-up echocardiography was not performed on
patients before hospital discharge after percutaneous mitral
balloon valvotomy. Thus, the impact of commissural calcium
on the immediate echocardiographic outcome, as reported
previously by Fatkin et al. (11), could not be performed.
An inherent bias of the study is the fact that all patients who
were being considered for percutaneous mitral balloon valvo-
tomy at this institution underwent scoring with the conven-
tional Abascal system first. Some patients with high scores may
have been eliminated, despite the appearance of the commis-
sures. Thus, the presence of commissural calcification as a lone
predictor of outcome needs prospective testing in a large group
of patients before this can be deemed applicable to all patients
with mitral stenosis.
Conclusions. The present study demonstrates that the
presence of commissural calcification identified by two-
dimensional echocardiography is a useful predictor of outcome
after percutaneous mitral balloon valvotomy. Patients with
evidence of calcium in a commissure have a lower survival rate
and a higher incidence of mitral valve replacement at interme-
diate follow-up. This simple observation may allow better
selection of patients for percutaneous mitral balloon valvot-
omy and provide a powerful adjunct to the present echocar-
diographic evaluation of mitral valve morphology.
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